Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
2
Neutral
7
Bullish
5
Bearish
25
Neutral
7
Bullish
14
Bearish
23
Neutral
0
Bullish
9
Bearish
23
Neutral
0
Bullish
9
Bearish
23
Neutral
0
Bullish
9
Bearish
23
Neutral
0
Bullish
9
Discovery themes featuring this stock
Supriya Lifescience Ltd (SUPRIYA) is currently trading at 853.30 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Supriya Lifescience is an India‑based API manufacturer and exporter that also operates formulation and CDMO/CMO capabilities, producing niche and commodity APIs across anesthetics, vitamins, cardiovascular, ADHD and other therapeutic segments while pursuing backward integration and regulated‑market filings to move up the value chain. Q1 FY'27 reported revenue of Rs. 190 crores, a 31% YoY increase, but EBITDA slipped to Rs. 47 crores (25% margin) due to temporary cost headwinds such as higher solvent, power and a retrospective solar subsidy charge of ~Rs. 4.5–5 crores; management says these are transient and margins should return to guided levels. Exports remain the company’s primary growth engine, contributing 81% of Q1 revenues with Asia at 39%, Europe 35% and LATAM 20%; management reports 72% of revenues are currently backward integrated, supporting margin resilience and supply‑chain control as they scale regulated‑market filings and new product launches. Material expansion and product catalysts are imminent: Phase‑1 Patalganga capex of ~Rs. 200 crores for API/formulation blocks, Ambernath undergoing EU audit in November with two liquid anesthetic formulation launches already started, plus pipeline products including contrast media and ADHD molecules expected to meaningfully ramp in H2 FY'27 and beyond.
Over the past 52 weeks, Supriya Lifescience Ltd has traded between a low of ₹545.65 and a high of ₹1,085.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Supriya Lifescience Ltd has a market capitalization of approximately 6,989.13. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Supriya Lifescience Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 35.23 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 6,989.13 Cr, Supriya Lifescience Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Supriya Lifescience Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Supriya Lifescience Ltd is 35.23. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Revenue from operations was ₹189.75 crore, total income was ₹192.40 crore, PBT was ₹40.79 crore, and net profit from continuing operations was ₹24.04 crore for the quarter ended June 30, 2026.
The 52-week high cited was ₹1,085.
FY26 revenue grew 19% YoY to ₹828 crore, as stated in the provided data.
Supriya Lifescience is an India‑based API manufacturer and exporter that also operates formulation and CDMO/CMO capabilities, producing niche and commodity APIs across anesthetics, vitamins, cardiovascular, ADHD and other therapeutic segments while pursuing backward integration and regulated‑market filings to move up the value chain.
Q1 FY'27 reported revenue of Rs. 190 crores, a 31% YoY increase, but EBITDA slipped to Rs. 47 crores (25% margin) due to temporary cost headwinds such as higher solvent, power and a retrospective solar subsidy charge of ~Rs. 4.5–5 crores; management says these are transient and margins should return to guided levels.
Exports remain the company’s primary growth engine, contributing 81% of Q1 revenues with Asia at 39%, Europe 35% and LATAM 20%; management reports 72% of revenues are currently backward integrated, supporting margin resilience and supply‑chain control as they scale regulated‑market filings and new product launches.
Material expansion and product catalysts are imminent: Phase‑1 Patalganga capex of ~Rs. 200 crores for API/formulation blocks, Ambernath undergoing EU audit in November with two liquid anesthetic formulation launches already started, plus pipeline products including contrast media and ADHD molecules expected to meaningfully ramp in H2 FY'27 and beyond.
Pharmaceuticals & Biotechnology
Pharmaceuticals
6,989 Cr
Low Risk
35.2
37.0
1.2
5.8
1,085.50
545.65
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
3430.60 | 7,987 Cr | 28.56 | 22.96 | 2.16 | 76.46 | 92.74 | 39.60 | ||
3181.10 | 7,346 Cr | 20.34 | 8.89 | 3.85 | 39.20 | 51.99 | 25.90 | ||
648.40 | 7,261 Cr | 43.61 | 6.09 | 0.15 | 12.49 | 18.55 | 10.52 | ||
853.30 | 6,989 Cr | 35.23 | 5.84 | 0.12 | 17.46 | 23.00 | 14.62 | ||
113.70 | 6,556 Cr | 34.79 | 4.75 | 0.17 | 13.65 | 15.70 | 8.17 | ||
378.00 | 6,140 Cr | 19.60 | 2.30 | 1.33 | 11.74 | 15.71 | 9.86 | ||
1035.80 | 6,013 Cr | 39.04 | 5.51 | 0.19 | 12.92 | 14.30 | 8.38 | ||
| Median: 7 Co. | — | 853.30 | 6,989 Cr | 34.79 | 5.84 | 0.19 | 13.65 | 18.55 | 10.52 |
